Loading clinical trials...
Loading clinical trials...
A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers
Conditions
Interventions
Nanoliposomal Irinotecan
Trifluridine and Tipiracil Hydrochloride
Locations
3
United States
Emory University Hospital Midtown
Atlanta, Georgia, United States
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States
Emory Saint Joseph's Hospital
Atlanta, Georgia, United States
Start Date
January 30, 2018
Primary Completion Date
June 28, 2025
Completion Date
November 28, 2025
Last Updated
January 7, 2025
NCT02600949
NCT06340711
NCT06696768
NCT06901531
NCT07409272
NCT07282912
Lead Sponsor
Emory University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions